Chronic Lymphocytic Leukemia | Specialty

Dr. Davids Discusses Ongoing Research With Ibrutinib Plus Venetoclax in CLL

May 15th 2019

Matthew S. Davids, MD, MMSc, associate director, Center for Chronic Lymphocytic Leukemia, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses ongoing research with ibrutinib plus venetoclax in chronic lymphocytic leukemia.

Post-Ibrutinib Treatments Show Promise in CLL

May 8th 2019

Sameem Abedin, MD, discusses the recent encouraging data in chronic lymphocytic leukemia with venetoclax, duvelisib, and acalabrutinib.

Acalabrutinib Improves PFS in Relapsed/Refractory CLL

May 7th 2019

Acalabrutinib improved progression-free survival compared with rituximab plus either idelalisib or bendamustine in previously treated patients with chronic lymphocytic leukemia, according to findings from the phase III ASCEND trial.

Dr. Brander on the Safety and Efficacy of Ibrutinib/Venetoclax in CLL

May 7th 2019

Danielle M. Brander, MD, assistant professor of medicine, Duke Cancer Institute, discusses the safety and efficacy of the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in patients with chronic lymphocytic leukemia (CLL).

Dr. Abedin Discusses Key Updates in CLL

May 2nd 2019

Sameem Abedin, MD, assistant professor, Medical College of Wisconsin, discusses key updates in the treatment of patients with chronic lymphocytic leukemia.

Novel Agents Show Enhanced Efficacy Across CLL Subtypes

April 19th 2019

Matthew S. Davids, MD, MMSc, discusses recent shifts in the chronic lymphocytic leukemia paradigm with the use of novel therapies and the need to increase personalized treatment with these agents.

Fee-for-Service Unlikely to Disappear Soon

April 15th 2019

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

Progress in Relapsed/Refractory CLL Could Pave Way for Upfront Advances

April 3rd 2019

Joseph D. Rosenblatt, MD, discusses how advances made in chronic lymphocytic leukemia are changing the outlook for patients and predicts what can be accomplished in the near future.

Dr. Barrientos Discusses Promising Agents in CLL

April 1st 2019

Jacqueline C. Barrientos, MD, associate professor, The Feinstein Institute for Medical Research, Northwell Health, discusses promising agents in the treatment of patients with chronic lymphocytic leukemia.

Experts Dissect 3 Practice-Changing Studies for Newly Diagnosed CLL

April 1st 2019

During an OncLive Peer Exchange®, a panel of CLL experts review findings from studies presented at the 2018 American Society of Hematology meeting in December: iLLUMINATE, Alliance A041202, and ECOG E1912.

Dr. Davids on Frontline Challenges in CLL

March 21st 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Wierda on Novel Therapies in Relapsed/Refractory CLL

March 13th 2019

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses novel therapies in patients with relapsed/refractory chronic lymphocytic leukemia.

Novel Regimens Take Precedence in Newly Diagnosed CLL

March 11th 2019

Matthew S. Davids, MD, MMSc, discusses methods for choosing between frontline therapies for patients with newly diagnosed chronic lymphocytic leukemia and highlights anticipated research in the field.

Dr. Davids Discusses Frontline Approaches in CLL

March 9th 2019

Matthew S. Davids, MD, MMSc, associate director, CLL Center, Dana-Farber Cancer Institute, assistant professor of medicine, Harvard Medical School, discusses frontline treatment approaches for patients with chronic lymphocytic leukemia.

Dr. Seymour on Promising Combinations in CLL

March 8th 2019

Erlene Seymour, MD, assistant professor of medicine, Karmanos Cancer Institute, Wayne State University, discusses promising combination therapies in the treatment of patients with chronic lymphocytic leukemia (CLL).

FDA Approval Sought for Venetoclax/Obinutuzumab Combo for Frontline CLL

March 7th 2019

A supplemental new drug application has been filed for the combination of venetoclax and obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia who also have coexisting medical conditions.

Dr. Wierda on Treatment of Relapsed/Refractory CLL

March 7th 2019

William G. Wierda, MD, PhD, professor, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses treatment options for patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Jacobs on Treating Graft-Versus-Host-Disease With Ibrutinib in CLL

March 6th 2019

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the use of ibrutinib (Imbruvica) in treating chronic graft-versus-host disease in patients with chronic lymphocytic leukemia (CLL).

BCL-2 Emerges as an Attractive Target in Solid and Hematologic Cancers

March 6th 2019

Based on the crucial role of BCL-2 family proteins in apoptosis regulation, targeting these proteins using BCL-2 inhibitors offers a potentially new therapeutic option for patients with various types of hematologic malignancies and, more recently, patients with solid tumors.

Using BTK Inhibitors in Community Practice

March 4th 2019